Luigi Tavazzi
Tavazzi, Luigi
Tavazzi, L. (Luigi)
Tavazzi, Luigi, 19..-....
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Tavazzi, L.
Tavazzi, Luigi, 1939-
VIAF ID: 49348746 (Personal)
Permalink: http://viaf.org/viaf/49348746
Preferred Forms
-
100 0 _
‡a
Luigi Tavazzi
-
200 _ |
‡a
Tavazzi
‡b
Luigi
-
200 _ 1 ‡a Tavazzi ‡b Luigi
-
100 1 _ ‡a Tavazzi, L.
-
100 1 _
‡a
Tavazzi, L.
‡q
(Luigi)
-
100 1 _
‡a
Tavazzi, L.
‡q
(Luigi)
-
100 1 _ ‡a Tavazzi, Luigi
-
100 1 _ ‡a Tavazzi, Luigi
-
100 1 _
‡a
Tavazzi, Luigi
-
100 1 _
‡a
Tavazzi, Luigi
-
100 1 _
‡a
Tavazzi, Luigi,
‡d
19..-....
-
100 1 _ ‡a Tavazzi, Luigi, ‡d 1939-
4xx's: Alternate Name Forms (5)
Works
| Title | Sources |
|---|---|
| The anaerobic threshold : physiological and clinical significance |
|
| Cardiac medication during pregnancy, data from the ROPAC |
|
| Efficacy and safety of ivabradine in chronic heart failure across the age spectrum : insights from the SHIFT study |
|
| Exercise testing and reconditioning in heart and lung disease : guest editors: Claudio F. Donner and Luigi Tavazzi |
|
| Heart failure, 181 questions and answers |
|
| International Symp. on the Clinical Value of the Anaerobic Threshold in Heart and Lung Diseases (1985 : Verzuno, Italy). The anaerobic threshold, 1986: |
|
| The Major clinical trials on thrombolysis for acute myocardial infarction |
|
| Mental stress as a trigger of cardiovascular events : [Veruno, Italy, October 19 and 20, 1989] |
|
| Physical training and ventricular dysfunction |
|
| Principales ensayos clínicos sobre trombólisis en el infarto agudo de miocardio |
|
| [The process of drug development. The "case" of spironolactone]. |
|
| Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial |
|
| Programme to improve the use of beta-blockers for heart failure in the elderly and in those with severe symptoms: results of the BRING-UP 2 Study |
|
| Progression of Renal Impairment and Chronic Kidney Disease in Chronic Heart Failure: An Analysis From GISSI-HF. |
|
| Radiofrequency catheter ablation and antiarrhythmic drug therapy: a prospective, randomized, 4-year follow-up trial: the APAF study |
|
| Randomized evaluation of intralesion versus intracoronary abciximab and aspiration thrombectomy in patients with ST-elevation myocardial infarction: The COCTAIL II trial. |
|
| Ranolazine, a new antianginal drug |
|
| Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). |
|
| Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations |
|
| Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure |
|
| Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study |
|
| Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction) |
|
| Real-time three-dimensional echocardiography as a novel approach to quantify left ventricular dyssynchrony: a comparison study with phase analysis of gated myocardial perfusion single photon emission computed tomography |
|
| Red blood cell oleic acid levels reflect olive oil intake while omega-3 levels reflect fish intake and the use of omega-3 acid ethyl esters: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Heart Failure trial |
|
| Regression of severe bare metal stent restenosis: IVUS and OCT findings. |
|
| Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study. |
|
| Reply |
|
| Reply: The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: more questions than answers? |
|
| Responders to cardiac resynchronization therapy with narrow or intermediate QRS complexes identified by simple echocardiographic indices of dyssynchrony: the DESIRE study |
|
| Results of mitral valve repair for Barlow disease (bileaflet prolapse) via right minithoracotomy versus conventional median sternotomy: A randomized trial |
|
| Right ventricular dysfunction in advanced heart failure |
|
| Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca |
|
| Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian Survey on Acute Heart Failure |
|
| The role of invasive electrophysiology in the management of patients with chronic heart failure. |
|
| The root of the deep and fast ongoing evolution of both structure and methodology of clinical research |
|
| Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations: the SENSE-HF trial |
|
| Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. |
|
| Should we revise our approach to 'optimal medical therapy'? The case of chronic heart failure |
|
| Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS). Rationale and design |
|
| Successful treatment of heart failure with devices requires collaboration |
|
| Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a sub-analysis of the CARE-HF trial |
|
| Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed |
|
| Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). |
|
| Therapeutic approach in patients with stable angina |
|
| Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk Model |
|
| Transcriptomic and proteomic analysis in the cardiovascular setting: unravelling the disease? |
|
| Treatment with inotropes and related prognosis in acute heart failure: contemporary data from the Italian Network on Heart Failure (IN-HF) Outcome registry |
|
| Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes |
|
| Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases |
|
| Trial-generated profiles for implantation of electrical devices in outpatients with heart failure: real-world prevalence and 1-year outcome |
|
| Tubular damage and worsening renal function in chronic heart failure |
|
| Update on ivabradine for heart failure |
|
| Uric acid: a cardiovascular risk factor in patients with recent myocardial infarction |
|
| Use of sirolimus-eluting stents for treatment of in-stent restenosis: long-term follow-up. |
|
| Usefulness and limits of transthoracic echocardiography in the evaluation of patients with primary and chronic thromboembolic pulmonary hypertension. |
|
| When should cardiologists suspect Anderson-Fabry disease? |
|
| Wine consumption and risk of cardiovascular events after myocardial infarction: Results from the GISSI-Prevenzione trial |
|
| β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure |
|
| The ω-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation trial--rationale and design |
|
| প্রত্যুত্তর |
|
